logous stem cell transplantation; children; CD34 monitoring Autologous peripheral blood (PB) stem cell apheresis is an established procedure. It is used to collect hematopoietic stem cells in both adult and pediatric patients with malignant diseases for autologous rescue following highdose chemotherapy. 1, 2 In general, a minimum of 2 Â 10 6 cells/kg prior to cryopreservation is thought to be necessary for successful autografting, although transplantation with doses of 1 Â 10 6 CD34 þ cells/kg has been shown to induce a sufficient immune recovery. Nevertheless, high doses of CD34 þ cells (45 Â 10 6 cells/kg) seem to improve the clinical outcome. 3, 4 A major consideration is that apheresis procedures bear risks and are not always well tolerated, especially in small children. Therefore, a minimum of aphereses with a maximum yield of CD34 þ cells should be strived for. For sufficient yields of CD34 þ hematopoietic stem cells, hematopoietic growth factors in combination with cytotoxic drugs are used to mobilize hematopoietic stem cells from bone marrow into the PB. The numbers of collected progenitor cells correlate well with the concentration of CD34 þ progenitor cells in PB on the day of apheresis, whereas white blood cell (WBC) counts are only weakly predictive. [5] [6] [7] [8] [9] [10] [11] To optimize yields, different modes of stem cell mobilization from the bone marrow have been tested. These include dose variation of G-CSF, cytotoxic, [12] [13] [14] steady-state 15, 16 and combined mobilization, 17 ,10 mode of administration (subcutaneous vs intravenous), type of growth factor (G-CSF vs GM-CSF 18, 19 ), the influence of large volume apheresis (LVA 20, 21 ), as well as timing of administration in terms of days or hours before apheresis. The timing of apheresis in terms of days of G-CSF mobilization has been optimized in adults. While healthy adults with daily G-CSF-doses of 3-23 mg/kg show a maximum of CD34 þ cells at about 5 days after the start of administration, patients after polychemotherapy show a similar maximum at about day 10. 22 In healthy adults, a circadian rhythm of G-CSF in the PB and CD34 þ cell concentrations in the bone marrow has been established, with peak values found at 2200 hours 23 for G-CSF and between 1000 and 1500 hours 24 for CD34 þ cells, respectively. Therefore, a peak in peripheral CD34 þ counts after G-CSF administration is to be expected. For adult healthy volunteers and adult patients, the optimum time of apheresis has been described at 3-30 h after G-CSF administration [25] [26] [27] [28] [29] [30] (Table 1) . Nevertheless, for children, the optimal time span between the last G-CSF dose and start of apheresis remains to be established. The aim of this prospective study was to optimize the timing of apheresis in terms of hours after G-CSF administration to achieve a high stem cell yield with a minimum of aphereses. For this purpose, the leukocyte and CD34 þ progenitor cell concentrations in the PB of 20 children with various malignancies were measured by flow cytometry at intervals of 1-2h within 12 h after G-CSF administration.
Patients and methods

Patients
We included 20 consecutive pediatric patients (nine female, 11 male) as shown in Table 2 . All patients were treated in our hospital for malignancies, including neuroblastoma with bone marrow involvement (n ¼ 12), Ewing's sarcoma (n ¼ 1), osteosarcoma relapse (n ¼ 2), PNET (n ¼ 2), rhabdomyosarcoma (n ¼ 1), Non-Hodgkin lymphoma (n ¼ 1) and hepatoblastoma (n ¼ 1). Median age was 3 1 2 years (range 1 2 -17 1 4 years) and median bodyweight was 16.5 kg (range 7.4-70 kg). During the mobilization phase, all patients were outpatients, coming to our outpatient department for G-CSF administration, WBC and CD34 þ cell concentration check every day. During the weekends, parents living far away had the opportunity to administer G-CSF on their own, checking WBC counts at a local hospital or practitioner. Patient #20 only failed to receive G-CSF on days 3 and 4; from day 5 until day 20, he received G-CSF in our outpatient department, so he was not excluded from the study ( Table 2) .
Monitoring of mobilization
Mobilization was performed after the 3rd-21st cycles of chemotherapy, following the therapy protocol for the underlying disease. Daily full G-CSF doses (Neupogen, Amgen, Munich, Germany) were given s.c. in the morning from day 1 after the end of chemotherapy until 2 days of apheresis. Doses were between 4.8 and 10.2 mg/kg (median, 7 mg/kg/day). Different doses (per bodyweight) of G-CSF were used in patients for reasons of compliance and dosage safety: G-CSF was instilled subcutaneously by nurses, or the parents of the patients during the weekends, and easy handling for the parents was provided by using just full or half ampoules in these cases. On the last day before apheresis, patients received G-CSF as a single (sd, n ¼ 9) or double (dd, n ¼ 11) daily administration, which was administered in equal doses in the morning and 12 h later. Patients #10 and #14 received this divided G-CSF administration i.v. for 4 h in our ward. When WBC counts had reached 1 Â 10 9 /l, the peripheral concentration of CD34 þ cells was measured. The 12 h CD34 þ monitoring was initiated on the day when CD34 þ cell concentration in PB reached at least 10/ml. Blood samples were drawn via central venous catheter systems at hours 0, 2, 4, 5, 6, 7, 8 and 10 after administration, and again before G-CSF-administration at 12 h. Patient No.2 missed blood sample taking at hour 10 and 12 during monitoring, and patients No. 10 and 11 at hour 10. In summary, 176 CD34 þ cell determinations in duplicate have been performed (total of 352). An automatic blood cell count was done immediately on a CELL DYN 1700 System (Abbott Diagnostics, Illinois, USA) in duplicate, in addition to the flow cytometric analysis. At 6-10 h after the end of monitoring, the first apheresis was performed using a CS 3000 cell separator (Baxter, Deerfield IL, US).
Flow cytometric analysis
Dual-platform measurement by two-fluorescence flow cytometry was performed for the first 13 patients. The last 
CD34 monitoring to optimize timing of auto PBSC in children K Bochennek et al seven patients were evaluated with both, dual-and singleplatform measurements. Moreover, to compare the correlation of single-and dual-platform CD34 þ concentration measurement, 234 PB samples from pediatric patients were analyzed for CD34 þ cell count by single-and dualplatform measurements using the Bland-Altman analysis.
Samples were incubated with 20 ml of fluorescein isothiocyanate-conjugated anti-CD45 monoclonal antibodies (Anti-Hle-1) and 20 ml of anti-CD34 monoclonal antibodies conjugated with phycoerythrine (Anti-HPCA-2, Clone 8G12, Beckton Dickinson, Germany) in dual platform, or 20 ml of the combined antibodies (Stem Kit, Coulter ImmunoTech, Marseille, France) in single platform, including Flowcount fluorospheres (Coulter ImmunoTech, Marseille, France). 7AAD staining was used to exclude dead cells. Samples were incubated for 20 min in the dark at room temperature. Erythrocytes were counted by erylysis reagent (8.29 g NH 4 Cl, 1 g KHCO 3 , 37.2 mg EDTANa 2 , distilled water, pH 7.3-7.4) and for buffering, DPBSBuffer (Bio Whittaker Europe) was used. Samples with a WBC counts greater than 20 000/ml were first diluted to 10 000/ml with buffer. At least 50 000 events where acquired in every single analysis. IgG-isocontrole control (CD45 FITC-IgG 1 -PE) in duplicate was performed parallel to every measuring point. Flow cytometric analysis was performed on a Coulter Epics XL with System II Software following the ISHAGE guidelines for stem cell quantitation. 33 In the dual-platform setting, CD34 þ cell concentration was calculated from WBC counts (CELL DYN 1700, Abbott Diagnostics, IL, USA) and relative CD34 þ cell concentration. In the single-platform setting, the CD34 þ cell concentration was calculated using Flow-Count fluorospheres as an internal standard.
Statistical analyses
Statistical analyses were performed using BIAS software (BIAS 7.07, Epsilon Verlag, Frankfurt, Germany). Graphs were created by GraphPadPrism version 4-00 for Windows (GraphPad Software, San Diego CA, USA, www.graphpad.com). The Bland-Altman test was used for correlating single-and dual-platform flowcytometric data. The Friedman test was used to analyze significance of hourly CD34 þ count for patterns of mobilization (POM) I and II patients. The Mann-Whitney U-test was performed to show differences in patient subpopulations. As Gaussian distribution could not be presupposed in this small group of patients, median and range were used to describe analytic parameters, and patient subpopulations were analyzed with the Pearson correlation test. Patient subpopulations were defined retrospectively. CD34 þ and leukocyte cell concentration were calculated as relative values, referring to the concentration before G-CSF administration (hour 0).
Results
Comparing single-vs dual-platform measurement
When comparing single-and dual-platform measurement of CD34 þ cell concentration in PB and PBSC, significant correlations were found (r ¼ 0.95, Po0.0001 in samples with 0-250 CD34 þ cells/ml, n ¼ 232). The Bland-Altman test yielded a significant accordance between single and dual platform as shown in Figure 1 (bias 0.51, s.d. of bias 12 in PB samples).
Leukocyte mobilization
Individual WBC mobilization varied strongly, without significantly discernible patterns. Patterns of WBC mobilization varied strongly between patients. All showed a total increase of leukocytes during the course of 12 h monitoring (Figure 2) . Overall, a peak of WBC counts was seen at 8 h after G-CSF administration, with four patients reaching their highest WBC counts before that. Of these, one had a maximum WBC counts before hour 5.
CD34 þ cell mobilization
The starting level of CD34 þ cells was between 8 and 862 cells/ml (mean 50.5/ml), CD34 þ cell concentration at the CD34 monitoring to optimize timing of auto PBSC in children K Bochennek et al end of monitoring was between 17 and 1032 cells/ml (mean 88/ml). Absolute WBC and CD34 þ cell concentration for each measurement is shown in Table 3 . The median maximum of CD34 þ cell concentration for all patients was found at the 10th hour after G-CSF administration (median increase compared to start: 150%, range 62-275%, Figure 2 , closed squares). After an initial increasing level of CD34 þ cells with a first peak about 4 h after G-CSF, a tendency towards a minimum at 5 h was found. In median, CD34 þ cell concentration reached a plateau level or started to decrease after reaching the maximum peak at the 10th hour after G-CSF (median 142%, range 40-287%). Notably, overall, the percentage of CD34 þ cell relative to leukocyte cell count did not rise markedly above starting levels within the first hours. It showed an increase between the 7th and 10th hour after G-CSF bolus of 0.56% of leukocytes in median of all patients at hour 0, decreasing to 0.42% at hour 7 and increasing from then until hour 10 and 12 to 0.48% ( Figure 2 ; Table 3 ).
POM I and POM II -two clinical POM
In spite of the interindividual variability, two POM were discernible. POM I was characterized by an initial increase of relative CD34 þ cell concentration (POM I, n ¼ 12), defined as a rise of CD34 þ cells above starting levels within the first 4 h of monitoring. POM II (n ¼ 8) showed an initial decrease in relative CD34 þ cell concentration, falling below starting concentrations within the first 4 h of monitoring (Figure 3a) .
Patients mobilizing with a POM I (Figure 3c ) showed a nonsignificant median increase until 4 h after G-CSF, falling to a minimum at 5 h after G-CSF, and rising cell concentrations again until 10 h after G-CSF administration. In this group, the concentration of CD34 þ cells was significantly above starting levels from hour 8 on to the end of monitoring (Po0.0002). No significant differences in mean CD34 þ cell concentration were found for any two adjoining hours, but hour 2 differed from hour 10 and hour 4 from hour 12. Two patients in the POM I group differed from the overall group by showing a maximum CD34 þ concentration at hours 5 and 7. The former fell below initial levels afterwards to reach starting concentrations again at hour 12. Five patients with POM I showed a decrease of CD34 þ cells below initial CD34 þ cell concentration at least once during the monitoring period.
The CD34 þ concentrations of the patients assigned to POM II initially decreased after G-CSF, then rose to a maximum at 10 h after administration (Figure 3d ). Only the CD34 þ concentrations at hour 10 were significantly higher than at hour 0 (Po0.04).
No significant differences in mean CD34 þ cell concentration were found for any two neighboring hours, but hour 2 differed from hour 8 significantly.
The two groups differed significantly in their relative C34 þ mobilization kinetics 2, 4, 5, 6 and 7 h post G-CSF (Po0.0001). While both reached a maximum at 10 h after G-CSF, the POM II group showed a significantly lower increase in CD34 þ concentrations (POM I median 174%, vs POM II median 120%; Po0.02) in relation to hour 0, and the absolute counts of CD34 þ cells during hours 8 to 12 did not differ between the groups. In both POM I and II, initial absolute CD34 þ cell count at hour 0 showed a broad distribution (POM I: 8-203/ml, POM II: 13-862/ml). Both POM were noticed in patients with high and low initial CD34 þ cell count. Absolute CD34 þ cell count did not correlate with POM at any time of monitoring. None of the absolute number of CD34 þ cells was found to distinguish POM I or POM II patients within the first hours of monitoring.
CD34 þ cell concentration in relation to WBC
Initial mobilization of leukocytes runs similar to the CD34 þ kinetic (Figure 3b) . In nine patients, an initial decrease below starting concentrations was observed around hour 2, while the others increased steadily (Po0.001); after hour 4, the two groups did not differ significantly. The initial development of the WBC counts (increase or decrease within the first 2 h) and the two different POM correlated significantly (P ¼ 0.004).
In the mean of all patients, WBC counts shows a much earlier and higher increase than CD34 þ cell count. While WBC has a median increase of almost 30% at 4 h compared to the start of apheresis, CD34 þ cell count is enhanced by 10% only. CD34 þ cell count relative to total WBC decreased from initially 0.8 to 0.6% in that time. However, leukocyte mobilization does not predict for the value of CD34 maximum level or the time point to reach this maximum value. Comparing CD34 þ and WBC concentration development for the whole time of monitoring (12 h), no significant correlation was found (Pearson P ¼ 0.72, Figure 2 , open squares).
CD34 þ cell mobilization in relation to various clinical parameters
Further retrospective statistical evaluation did not show any significant differences between POM I and POM II patients regarding age, sex, kind of tumor, number of premobilization chemotherapy cycles, G-CSF-dosage, initial CD34 þ concentration (at hour 0), total collected CD34 þ cells, cycles of apheresis, processed blood volume, CD34 þ cells/kg bodyweight per processed liter of blood or days of G-CSF mobilization.
Discussion
Although mobilization and apheresis of CD34 þ stem cells is a well-established procedure in clinical practice, it still bears risks and stress, especially for children. Some children show a very weak mobilization kinetic and never do reach the needed amount of CD34 þ stem cells (2 Â 10 6 CD34 þ / kg). Others need two, three or more sessions of apheresis, all bearing risks like allergic reactions, blood circulation problems, thrombosis and infections. Therefore, an optimized scheduling of leukapheresis both to maximize CD34 þ stem cell yield and minimize the apheresis procedures is still lacking.
CD34 monitoring to optimize timing of auto PBSC in children K Bochennek et al Table 3 The 12-h-monitoring results Absolute WBC counts ( Â 10 3 /ml/nl), absolute CD34+ cells (/ml) and patterns of mobilization (POM I or II) in all 20 patients.
Patient
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CD34 þ cell concentration in PB has been shown to correlate with CD34 þ cell concentration in the apheresis product and yield of leukaperesis. 5, 12, 13 Therefore, as a prerequisite for the optimum timing of the measurement of CD34 þ cells, both single and dual platforms have been discussed. While Moretti et al 34 favored the single-platform method, Barbosa et al 35 did not find a significant difference in their in-house evaluation. The dual-platform method correlated significantly with the single-platform method, which is increasingly used as a superior CD34 þ determination. Likewise, in our study, single-and dual-platform measurement resulted in significant correlating results.
We aimed to measure the circadian peak of circulating CD34 þ cells after G-CSF administration. Using a 12-h monitoring schedule in 20 pediatric patients, we found two patterns of mobilization (POM I and II), both peaked at 10 h post G-CSF. POM I showed an initial increase of CD34 þ cells and POM II an initial decrease in CD34 þ cells. So a 10-h time gap between G-CSF administration and apheresis would have been optimum for our patients.
Literature is scarce on the topic of hourly stem cell monitoring, and to our knowledge no similar studies like ours have been described so far. Therefore, comparison of data from the literature should be performed with caution, because mobilization data includes CD34 þ cell monitoring in steady state (n ¼ 5) or different chemotherapy mobilization regime (Table 1) . In addition, patients suffering from various diseases, as well as healthy donors, are included. Furthermore, Watts et al 30 use glycosylated G-CSF, while the other authors do not.
Two different tendencies for the timing of stem cell collection can be found: early (2-6 h after G-CSF) apheresis vs late (48 h after G-CSF) apheresis. Sato et al 27 showed that for healthy adult volunteers, CD34 þ collection should be performed after 4 h but never prior to 2 h after the last G-CSF administration. Fischer et al 31 confirmed this thesis, demonstrating a peak level of CD34 þ cells 4 h after G-CSF (12 mg/kg/d) administration in six breast cancer and lymphoma patients. Sekhsaria et al 28 did not find an increment of CD34 þ cells within the first 6 h after G-CSF (5 or 10 mg/kg/day) on the first day of mobilization. Thereby, a small pediatric group suffering from chronic granulomatosis is included in a huge healthy adult group cells following glycosylated G-CSF administration (5 mg/ kg/day, n ¼ 6) in healthy adults which reversed to an increase 4 h after G-CSF. The difference of glycosylated and nonglycosylated G-CSF is widely discussed, and Lefrere et al 36 did not see differences in mobilization regime in 126 retrospective patients (glycosylated n ¼ 65, nonglycosylated n ¼ 61). We used the nonglycosylated G-CSF available in our clinic.
Some of the publications show characteristics with tendencies to one or the other POM. Our patients mobilizing with POM II had a quite early minimum CD34 þ cell concentration as measured in the patients of Sato et al at 2 h post G-CSF, while patients with POM I had often a first maximum at 2-4 h post G-CSF, as shown by Watts et al 30 Watts even describes a mobilization pattern like our POM I for his patients, also matching patients described by Fischer et al 31 Like our POM I and POM II patients, Kiefer et al 25 describe a maximum later than 8 h post G-CSF. Sato et al 27 showed that apheresis should not be performed before the 4th hour after G-CSF, and Watts et al 30 concluded that G-CSF should not be used directly prior to apheresis. This is in accordance with the kinetic of our POM II patients, where we found lower CD34 þ concentration at hour 2 than at hour 0 after G-CSF administration. Therefore, the various mobilization kinetics in literature might just reflect the spectrum of different mobilization pattern in different subsets of patients and treatment protocols.
Another aspect of CD34 þ monitoring is the predictive value of hematological parameters for CD34 þ cell count in PBSC and yield of apheresis. As we have demonstrated, POM I and II correlate with the initial increase or decrease of the WBC. However, although WBC and CD34 þ mobilization kinetic seemed to elapse similarly, WBC mobilization does not predict for the value of CD34 maximum level or the time point to reach this maximum value. So unlike as presented in many publications for the daily mobilization kinetics, the hourly mobilization kinetics of leukocytes and CD34 þ cells should not be used as a predictive value for time of maximum CD34 þ cell count.
There was no relationship between POM I and II with regard to various clinical parameters, which is in accordance with similar calculations in adults but differs regarding G-CSF administration. Martines et al 37 showed better mobilization results using 10 mg/kg/day compared to 5 m/kg/day in lymphoma patients after salvage therapy. Arbona et al 38 and Kro¨ger et al 39 found a superior mobilization in patients with a divided dose of G-CSF compared with a similar single dose. However, Arbona describes the effect in adult allogenic donors and Kro¨ger in breast cancer patients, which may prevent a direct comparison. In our patients, we divided the dose on the last day before apheresis, but in about half of the cases we administered a full G-CSF dose twice, so results are not comparable with former studies. No significant effects on mobilization by doubling G-CSF dose on the last day of apheresis could be found.
For further studies, a standardized starting schedule for the monitoring should be considered, as our monitoring started very inhomogeneously between 0800 and 1800 hours. Additionally, the circadian variation of G-CSF plasma level and CD34 þ is described. 32, 23 As patients with POM II showed lower mean CD34 þ cell counts, a CD34 þ cell count at 0 and 4 h after G-CSF administration on the day before apheresis could give a hint of the need for adapted apheresis schedules.
In conclusion, we found two different patterns of CD34 þ mobilization kinetic in 20 pediatric patients, both peaking at 10 h post G-CSF. This time point should be recommended for the start of apheresis. However, a larger pediatric study with an extended monitoring schedule should be performed to refine the results.
